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A novel cytokine profile associated with cancer metastasis to mediastinal and
hilar lymph nodes identified using fine needle aspiration biopsy
Ali I. Saeed, MD, FCCP
Master of Science in Biomedical Science, University of New Mexico, 2015

Abstract:
Background: Cancer metastasis to mediastinal and hilar lymph nodes is
indicative of a poor prognosis. Serum or sputum biomarkers provide limited
information about cancer metastasis to lymph nodes. However, endobronchial
ultrasound guided fine needle aspiration (EBUS-FNA) biopsy is increasingly used
to sample lymph nodes for simultaneous cancer diagnosis and staging.
Objective: We compared cytokine expression in benign versus malignant
mediastinal and hilar lymph nodes using EBUS-FNA biopsy specimen.
Methods: In this prospective, single center study, we collected EBUS-FNA
biopsies from patients recruited using a convenience sampling approach.
Cytokines were assayed using Bio-Plex Pro human cancer biomarker panels 1
and 2 in a Bio-Rad 200 suspension array system in two phases. The unique
cytokine profile obtained from phase I for cancer metastasis was validated in
phase II.
Results: In phase I, analysis was performed using 18 specimens obtained from
10 study participants. After collection of additional 36 specimens from 18
participants, phase II cytokine analysis was performed on 54 specimens
collected from a total of 28 participants. Malignant and benign histologic
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diagnoses were established in 16 participants (primarily non-small cell lung
cancer) and 12 participants, respectively. Cytokine analysis showed repeated
significant elevation of follistatin (p 0.001), uPA (p<0.001), osteopontin (p<0.001),
HER2/neu (p<0.001), VEGFR-1 (p<0.001), HGF (p<0.001) and VEGF-A
(p<0.001) in malignant samples when compared to benign lymph nodes.
Conclusion: We have identified and validated a novel cytokine profile of
metastatic cancer in mediastinal and hilar lymph nodes. This will guide future
studies to detect cancer biomarkers in lymph nodes with the goals to improve the
diagnosis, treatment and prognosis of cancer metastasis.
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Introduction:
Cancer metastasis to lymph nodes is associated with poor prognosis,
especially in patients with lung cancer (1). Despite significant improvements in
the management and treatment of cancer patients, most deaths are due to
chemo-resistant metastasis (2). The phenotypic drift (3, 4) and intrinsic
heterogeneity of cancer cells (5, 6) contribute to the potential for metastasis and
development of resistance to standard treatments. It is thus important to
understand the pathogenesis of cancer metastasis on a cellular and molecular
level with a goal to develop novel therapies directed towards prevention and
treatment (7).
Increase in tumor size is associated with increased incidence of
metastasis to the regional lymph nodes (8). Lymph nodes initially act as a barrier
to the circulating cancer cells. Antigenicity of circulating cancer cells trigger the
development of a complex immune reaction with histopathology indicative of
follicular hyperplasia, sinus histiocytosis, lymph angiogenesis and foreign body
granuloma formation (9). The cross talk between cancer cells trying to seed into
the lymph nodes changes over time and a nurturing microenvironment in the
lymph node allows for growth of tumor cells (9). The factors leading to this
change are unknown.
Endobronchial ultrasound allows for real time fine needle aspiration (FNA)
biopsy of mediastinal and hilar lymph nodes. Nakajima and colleagues reported
expression of two cytokines in the FNA biopsy that correlated with ultrasound
characteristics of the mediastinal lymph node (10). Their work illustrated that
1

measuring cytokines in the mediastinal lymph node aspirate using EBUS is
feasible. The current study is based on the hypothesis that a cytokine signature
obtained from FNA biopsy of a mediastinal or hilar lymph node with cancer
metastasis differs from that of a benign lymph node. We aim to determine if we
can reliably identify a comprehensive panel of cytokines from lymph node
aspirates that can explain the change in lymph node microenvironment with
cancer metastasis. In addition, we outline a standardized approach for collection,
storage and processing of lymph node aspiration biopsy using multiplex
technology.
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Methods
Study design. The study was conducted in two phases. Phase I was conducted
to identify a unique cytokine panel and then validate the results in phase II using
a narrower panel of significantly different cytokines identified in phase I (Fig.1).
Fine needle aspiration biopsy specimens (third or fourth biopsy) were collected
from mediastinal or hilar lymph nodes for cytokine analysis.
Subjects: Study participants were recruited from an outpatient specialized lung
cancer clinic at a University Hospital in New Mexico using convenience sampling
method. Eligibility criteria for inclusion were ability to communicate in English, at
least 18 years of age, and enlarged mediastinal and hilar lymph nodes.
Information reagarding: age, gender, race/ethnicity, and smoking history was
obatined from each patient before the procedure. Informed consent was obtained
from each subject by the physician performing the procedure. This study was
approved by the Human Research Review Committee of the University of New
Mexico (UNM) Health Science Center and TRICORE Reference Laboratory
Research Review Committee.
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Figure 1: Study Outline
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Collection of aspiration biopsy samples: The aspiration biopsy specimens
were collected in sterilized vials (2ml). The collection protocol required use of air
in a 5 milliliter syringe to push the specimen out of the endobronchial aspiration
biopsy needle, so as to avoid excessive dilution. If necessary, a metal stylet was
used to push the specimen out of the biopsy needle. The specimens were
immediately placed on ice and delivered within two hours to the T1 laboratory of
the UNM Clinical and Translational Science Center (CTSC). Samples were
stored at -72°C until cytokine analysis was performed.
Histopathology of aspiration biopsy: The histologic diagnosis of the lymph
node aspiration biopsy was made by a staff pathologist at the University of New
Mexico. Patients with FNA biopsy showing polymorphous population of
lymphocytes or inadequate samples were referred for mediastinoscopy. If
mediastinoscopy was not done, or offered, then these patients were followed with
repeat contrast enhanced computed tomography scan of the chest in 3 to 6
months interval to confirm stability or resolution of mediastinal and hilar lymph
nodes. If the histopathology diagnosis was other than a malignancy, the
respective sample was included for cytokine and data analysis as a benign lymph
node. For lymph nodes with cancer metastasis, the primary sites of cancer were
recorded for descriptive analysis.
Analysis of lymph node aspirates: A Bio-Rad Bioplex 200 suspension array
system (Bio-Rad Laboratories, Inc., 171-000201) was used for both phases of
the study. The bead based Luminex technology allows for multiple protein
analysis in a single sample. The data are reported as median fluorescence
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intensity (MFI) and concentration (pg/ml). The concentration of unknown analytes
bound to fluorescent bead is proportional to the MFI of the reporter signal. The
experimental protocol allows for simultaneous reporting of standards, controls,
blanks and cytokines of interest in duplicate.

Figure 2: Streptavidin phyco-erytherin conjugate bead based “sandwich” essay

Analyte

Antibody

Laser

Bead

Streptavidin
PE cong.
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Phase 1 study was conducted using the Bio-Plex Pro human cancer biomarker
panels 1 and 2 that included 16 and 18 cytokines, respectively (Table1). Efforts
were made to process all specimens simultaneously according to the Bio-Plex
human cancer biomarker assay instructions and experiment protocol. Bio-Rad
Bioplex Data Pro software ® (Bio-Rad Laboratories, Inc., 171-001513) was used
for data analysis to identify the extreme values, data distribution and selection of
range. Statistical analysis: Descriptive statistics for patient specific variables and
diagnostic variables were obtained using the STATA 12 software® (StataCorp,
12.1, College Station, Texas 77845) and are expressed as mean ± standard
deviations. The analytical data for lung cancer cytokines was performed by using
both Bio-Rad Bioplex Data Pro software ® and STATA 12 software. Using
histopathological diagnosis of cancer as an outcome variable, data for each
cytokine was analyzed for normality of distribution. Non parametric analysis was
performed using the Wilcoxon rank-sum test for non-normally distributed
variables. Data for variables that were not normally distributed were expressed
as median and interquartile range. Benferroni correction was used to address
multiple comparisons. Phase II was conducted using the protocol described
above to replicate results in a narrower panel of cytokines identified to have a
significantly different expression with cancer metastasis when compared to
benign histology, in phase I

7

Table 1: Bioplex human cancer panel 1 and 2

HCP 1
sEGFR
FGF-basic
Follistin
G-CSF
HGF
sHER-2/neu
sIL-6α
Leptin
Osteopontin
PECAM-1
PDFG-AB/BA
Prolactin
SCF
sTIE-2
sVEGFR-1
sVEGFR-2

HCP 2
Angiopoientin -2
sCD40L
EGF
Endoglin
sFASL
HB-EGF
IGFBP-1
IL-6
IL-8
IL-18
PAI-1
PLGF
TGF-α
TNF-α
uPA
VEGF-A
VEGF-C
VEGF-D
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Results.
Cytokine expression in FNA biopsies from metastatic lymph nodes
compared to benign lymph nodes.
Phase I: Cytokine analysis was performed in 18 FNA biopsy specimens collected
from 10 patients that comprised seven FNA biopsies with polymorphous
population of lymphocytes and one right paratracheal mass with histologic
diagnosis of hamartoma. Ten mediastinal and hilar lymph node FNA biopsies
were positive for cancer metastasis from lung, esophagus and skin (Table 2).
Patients with cancer diagnosis were of older age compared to patients with a
benign diagnosis. There were no stastical significant differences of smoking or
abstinence between the two groups (Table3). The mean sample volume was 166
micro liters (µl). The volume of benign lymph node aspirates was greater than the
volume from lymph nodes with metastasis, but did not reach stastical
significance.
The concentrations of 10 of the 34 cytokines measured, using human cancer
panel 1 and 2 were significantly elevated in malignant samples versus benign
samples: osteopontin, prolactin, vascular endothelial growth factor receptor 1 and
granulocyte- colony stimulating factor (p <0.01). In addition, vascular endothelial
growth factor-A, urokinase plasminogen activator, follistatin, hepatocyte growth
factor, stem cell factor and human epidermal growth factor receptor 2
concentrations were significantly elevated in samples with cancer metastasis
(p<0.05) when compared to benign samples (Fig 3 and 4)

9

The concentrations of prolactin in three samples and concentrations of VEGFR-1
in two samples were found to be out of range and were rejected for stastical
analysis in phase I. (Table 4)
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Table 2: Phase I detail of lymph node station and histologic diagnosis

Patients

Lymph node

Histological diagnosis

Cancer Stage

Squamous cell

IIIA (lung)

station
Patient 1

R4

Carcinoma
Patient 2

R4 and 7

Adenocarcinoma

IIIA (esophageal)

Patient 3

L4

Adenocarcinoma (lung)

IIIA (lung)

Patient 4

R10, 7 and R11

Benign

Patient 5

R4

Benign

L4

Adenocarcinoma

Patient 6

R10 and R11

Squamous CA

(skin)

Patient 7

R12, R4 and L4

Benign

CT chest with

IIIB IV (lung)

resolution
at 6 months
Patient 8

R4

Adenocarcinoma

IV (lung)

Patient 9

R4

Benign

(hamartoma)

Patient 10

7

Squamous cell

IIIB (lung)

Carcinoma
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Table 3: Phase I patient characteristics, based on histologic diagnosis

Variables

Patients

Diagnosis

p value

Benign

Metastasis

Total

10

3

7

Male

7

2

5

Female

3

1

2

Age, years*

68.7 (9.8)

63.5 (10.4)

73 (7.3)

0.03

Smoking, years *

31.2 (20.45) 21.8 (23.7)

38.7 (14.6)

0.07

25.2 (19.9)

0.52

Quit Smoking, years* 28 (20.1)

31.5 (21.2)

* Mean and standard deviation
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Table 4: Significant cytokines identified on analysis of 18 initial specimens
(8 benign and 10 malignant)

Analytes

Benign, pg/ml
(n=8)

Malignant, pg/ml
(n=10)

p value**

uPA

*64 (42 - 96)

360 (85 -1117)

0.013

VEGF-A

1063 (732 – 1927)

7049 (1540 – 20863)

0.026

Follistatin

438 (304 – 563)

1213 (558 – 2110)

0.013

G-CSF

12.5 (9.3 – 20.6)

38.2 (27 – 54.3)

0.0077

HGF

1540 (1172 – 1826)

3670 (1842 – 11480)

0.016

Osteopontin 1704 (790 – 3754)

5344 (2558 – 38952)

0.0099

Prolactin#

1262 (932 – 1664)

2732 (2028 – 4467)

0.0038

SCF

75 (51 -103)

113 (89 – 192)

0.033

HER2/neu

2577 (1873 – 3292)

9036 (3362 – 13466)

0.013

VEGFR-1$

866 (520 – 1378)

9498 (2946 -18532)

0.0045

* Median and interquartile range (25th and 75th percentiles)
** Benferroni correction for multiple comparisons with statically significant p value
of 0.0017 (34 cytokines)
#

Prolactin, valid benign specimen (n=7) and valid malignant specimens (n=8)

$

VEGFR-1, valid malignant samples (n=8)
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Figure 3: Phase I analysis with significant elevation of cytokines in human cancer
panel 1*

*Standard error of the mean
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Figure 4: Phase I analysis with significant elevation of cytokines in human cancer
panel 2*

*Standard error of the mean
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Phase II: After collection of an additional 36 FNA biopsy specimens, final
analysis was performed using 54 mediastinal and hilar lymph node aspiration
biopsy specimens collected from 28 eligible patients (19 men and 9 women,
Table 1). Histologic diagnosis of metastatic cancer was established in 25
specimens (9 adenocarcinoma lung, 5 squamous cell carcinoma lung, 4 small
cell carcinoma lung, 1 adenocarcinoma breast, and 2 each of adenocarcinoma
colorectal and esophagus, and squamous cell cancer from skin). Twenty nine
FNA biopsies were found to have a benign histologic diagnosis (1 hamartoma, 1
sarcoid, 2 granulomas and 8 mature lymphocytes). Patients with cancer had a
higher pack year history of smoking than those with benign diagnoses (Table 5).
The distribution of age and years of abstinence from smoking did not differ
between the two groups.
The primary purpose of this approach was to validate the results of initially
identified 10 cytokines in phase I. uPA, VEGF- A, follistatin, HGF, osteopontin,
Her2/neu and VEGFR-1 cytokine concentration were again significantly elevated
in metastatic versus benign lymph nodes (Table 6). Using a Benferroni correction
value of 0.005 for 10 repeated comparisons; all 7 out of 10 cytokine
concentrations were significantly different between the two groups with the
greater concentrations found in the cancer group.
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Table 5: Phase II patient characteristics, based on histologic diagnosis

Variables

Patients

Diagnosis
Benign

Metastasis

Total

28

12

16

Male

19

11

8

9

1

8

Female

P value

Age, years*

64.2 (9.6)

62.4 (9.2)

65.6 (10.0)

0.39

Smoking, years *

25.8 (19.9)

17 (19.6)

32.3 (18.0)

0.04

13.3 (18.1)

12.4 (18.8)

0.89

Quit Smoking, years* 12.81 (18.23)

* Mean ± standard deviation
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Table 6: Significant cytokines identified in 54 specimens (29 benign and 25
malignant)

Analytes

Benign, pg/ml
(n=29)

Malignant, pg/ml
(n=25)

p value**

uPA

*158 (73 – 188)

442 (195 – 5091)

0.0000068

VEGF-A

488 (204 – 914)

12941 (1562 – 26720)

0.000000055

Follistatin

723 (438 - 937)

1216 (660 - 3961)

0.0012

HGF

2339 (1358 - 3742)

6190 (2298 – 10014)

0.00032

Osteopontin 5548 (1783 – 19186)

386230 (5344 – 70901)

0.00079

HER2/neu

3242 (1950 – 4007)

8198 (4130 – 13693)

0.0000040

VEGFR-1#

766 (445 – 1276)

9678 (2004 – 15120)

0.00000021

* Median and interquartile range (25th and 75th percentile)
** Benferroni correction for multiple comparisons with statically significant p value
of 0.005 (ten cytokines identified on initial analysis)
#

VEGFR-1, valid benign samples (n=25) and valid malignant samples (n=23)
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Figure 5: Phase II analysis with significant elevation of cytokines in human
cancer panel 1*

*Standard error of the mean
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Figure 6: Phase II analysis with significant elevation of cytokines in human
cancer panel 2*

*Standard error of the mean
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Cytokine analysis in FNA biopsies non-small cell lung cancer metastasis
(adenocarcinoma and squamous cell carcinoma) compared to benign
lymph nodes.
To test an additional hypothesis that non-small cell lung cancer (NSCLC)
metastasis to mediastinal and hilar lymph nodes express a unique cytokine
signature, different from benign lymph nodes, a subgroup analysis was
performed using data with NSCLC metastasis. Fourteen specimens with
histology proven NSCLC diagnosis obtained from eight patients were compared
to 29 benign lymph node aspiration biopsy samples, using the same approach as
outlined for all types of cancer. Except for follistatin, which was no longer
significant, the cytokine expression in lymph nodes with non-small cell lung
cancer was identical to all cancer metastases after correction for Benferroni error
(Table 7).
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Table 7: Subgroup analysis, in specimens with non- small cell lung cancer

Analytes

Benign, pg/ml
(n=29)

Malignant, pg/ml
(n=14)

p value**

uPA

*158 (73 – 188)

625 (311 – 15415)

0.000000064

VEGF-A

488 (204 – 914)

15980 (1570 – 29991)

0.00000082

HGF

2339 (1358 – 3742)

5251 (2134 – 7241)

0.0034

Osteopontin 5548 (1783– 19186)

33669 (17844 -50215) 0.0014

HER2/neu

3242 (1950 – 4007)

10012 (4475 – 16765)

0.00062

VEGFR-1#

766 (445 – 1276)

8495 (2232 – 14904)

0.00022

* Median and interquartile range (25th and 75th percentiles)
** Benferroni correction for multiple comparisons with statically significant p value
of 0.005
#

VEGFR-1, valid benign samples (n=25) and valid malignant samples (n=12)
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Figure 7: Phase II subgroup analysis with significant elevation of cytokines in
human cancer panel 1*

*Standard error of the mean
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Figure 8: Phase II subgroup analysis with significant elevation of cytokines in
human cancer panel 2*

* Standard error of the mean
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Discussion:
The data presented in the current study shows that the cytokine
expression of lymph nodes with metastasis differs from a benign lymph node. It is
important to understand the change in the microenvironment of a regional lymph
node upon exposure to circulating cancer cells with varying metastasis potential.
It is unknown why a lymph node initially acts as a barrier by providing a repulsive,
antigenic response to the circulating cancer cells and then transitions by
providing a nurturing microenvironment to another cancer cell from the same site
allowing establishment of metastasis.
However, it is well known that a primary cancer site has a heterogeneous
population of malignant cells (11), with different metastatic potentials dependent
upon the mutations (deletions, translocations, and amplifications) (12, 13). Over
the last two decades, scientists have investigated the role of cytokines
expressed by cancer cells especially for angiogenesis, lymphangiogenesis but
more importantly understand the cytokine interaction of cancer cells with
surrounding mesenchymal cells, dendritic cells, macrophages, fibroblast and
extracellular matrix (14). In this study we demonstrate that the inflammatory
microenvironment, in terms of cytokine expression of lymph node with cancer
metastasis, is very different from a benign lymph node. This allows for the
opportunity to understand the pathophysiology at a molecular level and to
develop novel cytokine-based strategies in preventing, delaying and even
reversing metastasis.
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The seed and soil theory initially proposed by Stephen Paget’s in 1889
encompasses crosstalk between the circulating cancer cell and site (organ) of
metastasis. Rodent models of cancer have revealed that certain tumor types tend
to metastasize to specific organs independently of number of cancer cells,
vascularity and blood flow. This finding confirms that site of metastasis is
dependent not only on the metastatic potential of cancer cells but also the
microenvironment of host tissue (15). Several clinical studies have shown that In
certain tumors spread preferentially via the lymphatic route into the draining
lymph nodes including malignant melanoma of skin, lung cancer, head and neck,
breast, colorectal and squamous cell carcinoma of uterine cervix (14).
Modulations of certain cytokines are well understood in cancer metastasis.
A cancer cell requires down regulation of e-cadherin in the primary tumor site to
decrease cohesiveness with surrounding cells (16). It then abuts the lining of
capillaries and lymphatics to gain entry into the circulation. Once in the lymphatic
circulation, it enters into the medullary sinus, medulla and cortex through the
afferent lymphatic of the regional lymph nodes (9). At this point the lymph node
can mount a barrier response to the antigenicity of the cancer cell. Reactive
follicular hyperplasia, sinus histiocytosis and even granuloma formation is
commonly seen in the regional draining lymph nodes (9).
Up regulation of certain cytokines is associated with increased metastasis.
Over expression of VEGF-C in patients with breast cancer is associated with
enhanced metastasis into the draining lymph nodes and lung (17). VEGF-D
induces angiogenesis and lymphangiogenesis in primary tumor. VEGF-D
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expression on tumor cells enhances metastasis potential (18). Role of VEGF-A in
promotion of lymph node angiogenesis remain unclear (19). Angiopoientin 1 and
2 expression is important in angiogenesis and are also found to play an important
role in lymphangiogenesis and metastasis (20). Chemokine expression is often
associated in enhanced lymphatic metastasis (21) and possibly acts as homing
signal causing increased metastasis (22-25).
The current study focused on understanding cytokine expression in cancer
metastasis in the lymph node (lung, breast, colon, skin and esophageal). In a
subgroup analysis comparing cytokine expression of different cancers with
metastasis to lymph nodes, we did not find significant difference in cytokine
expression. This allows for generation of hypothesis that possibly lymph node
behaves similarly for any cancer cell presenting to the lymph node, irrespective
of the primary site of origin. On key limitation of the above stated hypothesis is
the limited number of non-lung cancer biopsy specimens, as we also did not find
statistical significant difference in cytokine expression of all cancer metastasis
when compared to lung cancer. It is also unclear if the cytokines expression is
from cancer cells or lymphoid cells. In the current study we have used the
number of lymph node aspiration biopsy specimens “n” to perform stastical
analysis. On an average we collected FNA- biopsy specimens from two different
lymph node stations per patient while performing endobronchial ultrasound to
diagnose or stage cancer. It is an ongoing debate if the number for analysis “n”
should be patients and not lymph node station, there is mostly a correlation of
histologic results. In the current study we identified two patents, one with breast
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cancer and another with NSCLC, one lymph node station histology was positive
for malignancy on FNA biopsy and other lymph node station (contralateral)
histology without metastasis. On review of literature most cytokine analysis were
performed using collected specimens as number of specimens for stastical
analysis. The strengths of our study include a two phased approach that
included validation, strict quality control, and application of Benferroni correction.
We anticipate that the above findings will help researchers to use FNA
biopsy obtained using endobronchial ultrasound as a feasible research specimen
to conduct cytokine expression studies to predict the lymph node’s malignant
potential. This will also provide opportunities for development of novel
biomarkers for selection and response to current treatment regimens and
possible development of novel drugs in prevention, delay and even reversal of
metastasis in hilar and mediastinal lymph nodes.
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